Virtual medical assistant developer MedWhat has hit back at investors including Stanford University and its StartX Fund with allegations they broke the law on eight separate counts.

Onyx Therapeutics-backed autoimmune drug developer Kezar Life Sciences has closed its initial public offering at $86.3m.

Steven Chackowicz will be responsible for identifying and commercialising research in the medical device sector.

The transplant-based medicine developer, backed by Alphabet, Partners Healthcare and Access Industries, floated in the middle of its range.

Parkwalk has returned to back three-dimensional imaging developer Fuel3D as the Oxford spinout continues work on a scanner than can accurately detail sub-cutaneous tumours.

The UCL spinout has priced its shares at the top of its range and secured $150m in proceeds, up from its initial target of $100m.